Competing designs for phase I clinical trials: a review.
about
Designs for single- or multiple-agent phase I trials.Escalation with overdose control using time to toxicity for cancer phase I clinical trials.Incorporating individual and collective ethics into phase I cancer trial designs.Moving a Carbohydrate Mimetic Peptide into the clinicA statistical evaluation of dose expansion cohorts in phase I clinical trials.Bayesian continual reassessment method for dose-finding trials infusing T cells with limited sample size.Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in Phase I clinical trials.Interactive Software "Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)" for Cancer Phase I Clinical Trials.Bayesian Dose Finding for Combined Drugs with Discrete and Continuous Doses.Web-based tools for finding optimal designs in biomedical studies.Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.Dose-toxicity models in oncology.Adaptive designs for dual-agent phase I dose-escalation studies.Dose-finding methods for Phase I clinical trials using pharmacokinetics in small populations.A two-dimensional biased coin design for dual-agent dose-finding trials.Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.Tolerability and pharmacokinetic profile of a novel benzene-poly-carboxylic acids complex with cis-diammineplatinum (II) dichloride in dogs with malignant mammary tumours.A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies.Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading.Parametric non-mixture cure models for schedule finding of therapeutic agents.Incorporating adverse event relatedness into dose-finding clinical trial designs.An adaptive optimal design for the E(max) model and its application in clinical trials.An adaptive model switching approach for phase I dose-finding trials.Some notable properties of the standard oncology Phase I design.Targeting tumor-associated carbohydrate antigens: a phase I study of a carbohydrate mimetic-peptide vaccine in stage IV breast cancer subjects.Statistical controversies in clinical research: building the bridge to phase II-efficacy estimation in dose-expansion cohorts.A Bayesian approach for dose-escalation in a Phase I clinical trial incorporating pharmacodynamic endpoints.Fractional dose-finding methods with late-onset toxicity in phase I clinical trials.A bivariate Bayesian dose-finding procedure applied to a seamless phase I/II trial in rheumatoid arthritis.Dose-finding in phase I clinical trials based on toxicity probability intervals.Implementation of a Bayesian design in a dose-escalation study of an experimental agent in healthy volunteers.An evaluation of a bayesian method of dose escalation based on bivariate binary responses.A placebo-controlled Bayesian dose finding design based on continuous reassessment method with application to stroke research.Methodology and Application of Adaptive and Sequential Approaches in Contemporary Clinical TrialsNumber of Patients per Cohort and Sample Size Considerations Using Dose Escalation with Overdose Control
P2860
Q30434355-E7DAC90F-8899-4A8C-AD64-AC3771B92703Q35129807-13B6ADB9-4678-4774-A09E-C21BC138AF96Q35797245-1CAC0671-7455-43A2-BBB7-4C92FB0CD609Q35887538-1A64E45A-5F3D-4694-A913-97C2B32FE264Q36047412-37AE7E2B-9A51-45D1-866D-A0AA0FB68A3FQ36408968-FBAC333D-FDE5-4780-AA60-9C86D71A5E4CQ36621961-1E8EBBA5-A853-4580-A831-13C830DECE69Q36913137-76FA6AB1-2B4A-496C-8CA0-E63DA1506921Q36924666-4657750C-A472-4F6C-9228-6F7754690350Q37099409-F4583223-A294-4736-B5E6-298580448A56Q37192884-0D97D2C6-23F0-4DAD-8789-8CA27EFC9FFBQ37523183-E4C1DBDD-57A7-42DB-9A78-357FD437D3D0Q37829437-5C84692C-B9DB-414D-8CA7-B3084771AD11Q38090897-CB896DEA-5BAA-41E6-82EE-B4435A6BA62BQ40283645-6395D04B-B5D4-477B-914A-170E36C0CFD0Q40749503-A239EF2F-2FE4-4E2B-BB85-B15EC203DB11Q41151711-7FFF1C2C-0DB1-4F52-B817-BDD37313BC82Q41435545-C63B66FC-13C1-47E8-98C1-E308B29F3E44Q41790792-A1262FD3-68FB-4249-ADBD-7E77D69EAF19Q42031348-56220A0F-F336-44FD-ADF1-43C04381E998Q42737207-B46B5191-6516-4A50-BEE9-C885523F3009Q43681160-5D36082E-7839-4D87-B535-A6EFB5999CD5Q43740449-43C10C70-6FE7-4F19-A149-058C03910CC9Q45698393-F82AF15C-6CAC-433C-84AF-4651106E10F1Q45978270-7E08029E-DC60-48E2-B6A9-EC1E4FD9ACDFQ47135344-32C05018-4ED8-4DE3-9E63-B19868CBC34BQ47364031-0346C8CA-82DA-4C6D-AF94-FC92CFAD7F80Q48374430-C1D1EF70-A7F2-4DD7-AE79-F1CEBAC08F34Q51198034-12C4C9DF-9251-4962-81EE-15F0F026C769Q51317650-9233C24E-3128-4793-943A-BCF4E5D60559Q51907391-BD4E26CD-3DC6-45EA-BFB5-A4FA9CE2AFBAQ51911223-4D6CC562-EE14-429D-AF31-C85E38941077Q51982756-A153F2F6-36BD-45FF-8B68-33F572597591Q55419507-B90BDA3E-7AB6-4C0C-B313-5234521270C8Q58910970-C42F17F8-DECD-49A7-9BE6-A816F3BD94ABQ58910979-81B23AFC-5B2E-4EF5-B985-41612569A2FC
P2860
Competing designs for phase I clinical trials: a review.
description
2002 nî lūn-bûn
@nan
2002 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Competing designs for phase I clinical trials: a review.
@ast
Competing designs for phase I clinical trials: a review.
@en
Competing designs for phase I clinical trials: a review.
@nl
type
label
Competing designs for phase I clinical trials: a review.
@ast
Competing designs for phase I clinical trials: a review.
@en
Competing designs for phase I clinical trials: a review.
@nl
prefLabel
Competing designs for phase I clinical trials: a review.
@ast
Competing designs for phase I clinical trials: a review.
@en
Competing designs for phase I clinical trials: a review.
@nl
P2860
P356
P1476
Competing designs for phase I clinical trials: a review.
@en
P2093
Linda M Haines
William F Rosenberger
P2860
P304
P356
10.1002/SIM.1229
P407
P577
2002-09-01T00:00:00Z